Pontine Glioma Drug Market
Global Pontine Glioma Drug Market Size, Share & Trends Analysis Report By Type (Diffuse Brain Stem Glioma, Focal Brain Stem Glioma and Recurrent Brain Stem Glioma), and By Application (Cancer Research Institutes, Diagnostic Laboratories and Hospitals) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global pontine glioma drug market is anticipated to grow at a significant CAGR of 3.9% during the forecast period. The rising prevalence of pontine glioma around the globe is expected to drive demand for pontine glioma drugs across the globe over the forecast period. Pontine glioma is a rare, fast-growing tumour that develops in glial cells in the pons, a region of the brain stem. Diffuse intrinsic pontine gliomas (DIPG) also have a proclivity for spreading to surrounding tissue and other areas of the brain stem. For instance, as per the information provided by National Center for Biotechnology Information (NCBI) in 2021, around 300 children in the US suffer each year, and DIPG is one of the leading causes of death. DIPG affects approximately 80% of people and the sickness occurs in 1 to 2 cases per 100,000 people.
Impact of COVID-19 Pandemic on Global Pontine Glioma Drug Market
The global market for pontine glioma drug had benefited from the COVID-19 pandemic. With regard to the COVID-19 pandemic situation, an increase in drug demand has been observed. Additionally, key market players present in this market have increased their R&D skills, and increased their manufacturing management and quality control investments which in turn is supporting the market growth.
Segmental Outlook
The global pontine glioma drug market is segmented based on classification and application. Based on the classification, the market is sub-segmented into diffuse brain stem glioma, focal brain stem glioma and recurrent brain stem glioma. Based on the application, the market is sub-segmented into the cancer research institutes, diagnostic laboratories and hospitals. Due to growing sales of prescription-based pharmaceuticals and rising patient visits for treatment of oncology disorders, particularly brain cancer, the hospital segment gained a substantial share globally.
Global Pontine Glioma Drug Market Share by Classification, 2021 (%)
The Diffuse Brain Stem Glioma Holds the Prominent Share in the Global Pontine Glioma Drug Market
The diffuse brain stem glioma segment holds a significant market share and is anticipated to grow significantly during the forecast period in the global pontine glioma drug market in the classification segment. This is the most prevalent type of glioma in the brain stem. Diffuse brainstem gliomas account for 15–20% of all CNS tumours in children and are one of the leading causes of death in these children. This tumour develops freely across the pons and frequently extends to the midbrain, medulla, or other areas of the brain. These are often high-grade tumours and are aggressive and contain cells that appear to be aberrant.
Regional Outlooks
The global pontine glioma drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Pontine Glioma Drug Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Pontine Glioma Drug Market
Asia-Pacific region holds a significant share and is anticipated to grow fastest during the forecast period in the pontine glioma drug market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the pontine glioma drug market. Additionally, due to expanding demand for oncology treatments, rising incidence of brain cancer, and an ageing population in countries such as China and Japan, the Asia Pacific impacts the growth of the market. For instance, according to the information provided by Janssen Asia Pacific, a division of Johnson & Johnson, which highlighted information that each year, Asia Pacific is responsible for half of the global new cancer cases, and cancer-related fatalities in Asia and it is anticipated to rise by 36% by 2030.
Market Players Outlook
The major companies serving the global pontine glioma drug market include AROG Pharmaceuticals, INC., Burzynski Research Institue, Inc., Loxo Oncology, Medicenna Therapeutics and Pfizer. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2021, Oblato, Inc., had received fast track designation from the FDA for OKN-007. It is a trademarked treatment for Diffuse Intrinsic Pontine Glioma (DIPG).
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global pontine glioma drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Pontine Glioma Drug Market
- Recovery Scenario of Global Pontine Glioma Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AROG Pharmaceuticals, INC.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Burzynski Research Institute, Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Loxo Oncology
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Medicenna Therapeutics
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Pfizer Inc.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Pontine Glioma Drug Market by Classification
4.1.1. Diffuse Brain Stem Glioma
4.1.2. Focal Brain Stem Glioma
4.1.3. Recurrent Brain Stem Glioma
4.2. Global Pontine Glioma Drug Market by Application
4.2.1. Cancer Research Institutes
4.2.2. Diagnostic Laboratories
4.2.3. Hospitals
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.
6.2. Adastra Pharmaceuticals
6.3. Alcyone Therapeutics, Inc.
6.4. Apexigen
6.5. AstraZeneca
6.6. Bayer AG
6.7. Boehringer Ingelheim International GmbH
6.8. Bristol-Myers Squibb Co.
6.9. F. Hoffmann-La Roche Ltd.
6.10. Kazia Therapeutics Ltd.
6.11. Mateon Therapeutics Inc.
6.12. Oblato, Inc.
6.13. Penn Medicine
6.14. Sanofi Inc.
1. GLOBAL PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY CLASSIFICATION, 2021-2028 ($ MILLION)
2. GLOBAL DIFFUSE BRAIN STEM GLIOMA PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL FOCAL BRAIN STEM GLIOMA PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL RECURRENT BRAIN STEM GLIOMA PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
6. GLOBAL CANCER RESEARCH INSTITUTES PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL DIAGNOSTIC LABORATORIES PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL HOSPITALS PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY CLASSIFICATION, 2021-2028 ($ MILLION)
12. NORTH AMERICAN PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. EUROPEAN PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY CLASSIFICATION, 2021-2028 ($ MILLION)
15. EUROPEAN PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY CLASSIFICATION, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. REST OF THE WORLD PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY CLASSIFICATION, 2021-2028 ($ MILLION)
21. REST OF THE WORLD PONTINE GLIOMA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL PONTINE GLIOMA DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL PONTINE GLIOMA DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL PONTINE GLIOMA DRUG MARKET, 2022-2028 (%)
4. GLOBAL PONTINE GLIOMA DRUG MARKET SHARE BY CLASSIFICATION, 2021 VS 2028 (%)
5. GLOBAL DIFFUSE BRAIN STEM PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL FOCAL BRAIN STEM PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL RECURRENT BRAIN STEM PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL PONTINE GLIOMA DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
9. GLOBAL CANCER RESEARCH INSTITUTES PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL DIAGNOSTIC LABORATORIES PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL HOSPITALS PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL PONTINE GLIOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. US PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
14. CANADA PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
15. UK PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. FRANCE PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. GERMANY PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. ITALY PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. SPAIN PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. REST OF EUROPE PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. INDIA PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. CHINA PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. JAPAN PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. SOUTH KOREA PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF ASIA-PACIFIC PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD PONTINE GLIOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
